Previous studies showed that BCAT1 could inhibit glutaminase-specific sensitization of IDH-mutant glioma cells to oxidative stress in vitro and to radiation in vitro and in vivo (Tönjes et al., 2013; Chaumeil et al., 2014; McBrayer et al., 2018). Here, BCAT1 is linked to central nervous system cancer.